Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.
To save families from cancer.
Board of Directors
Our brand assets – logos, icons, designs, software, screen displays, trade dress, products, software, services, and any other brand features and elements, whether registered or unregistered – are protected by trade dress, copyright, patent and trade mark laws, and various other international intellectual property rights and unfair competition laws.
Our 100+ granted patents extend to 30 countries and our patent applications are in progress in 120 countries. These include: PCT/GB2010/001472, GB2474319, EP 2462561, US 9,008,382, CN 201080044509; PCT/GB2011/001658, US 9,361,683, EP 2646980; PCT/GB2014/000217, EP3005298, US 9,865,067, CN2014800437596; PCT/IB/2016/056669, EP16795434, US 10,733,724, CN201680077530; PCT/IB2017/054382, EP2017757879, US10,984,528, CN2017800448113; PCT/IB2018/054462, EP18743083, US 11,246,550, CN201880046575; PCT/IB2018/058663, EP18812262; US15/733,058; CN201880068341; PCT/IB2020/058247; US 17/640,762; EP2020771617, CN2020800624210; PCT/IB2020/051340; PCT/IB2020/061379, CN2020800798528, US17/782,162, EP202828311; PCT/IB2021/060509; PCT/IB2022/057460; PCT/IB2021/059286; PCT/IB2022/053697; PCT/IB2021/056019; GB2204120.6; GB2117222.6.
Our trademarks are registered in 39 countries and include: Volpara®, VDG®, Enterprise®, Tempara®, MRS®, MRSQuest®, Aspen™, and CRA Health®. Other trademarks and service marks that we use include volparadensity™, volpararisk™, volparalive!™, volparadose™, volparapressure™, volparapositioning™, TruDensity®, TruPGMI®, TruPressure®, TruRadDose®, volpara analytics™, volpara scorecard™, volpara patient hub™, volpara lung™, Volpara Solutions™, Volpara Enterprise DDP™, Volpara Analytics™, Volpara Density Grade™, and Volpara Platform™, Predict Monitor Detect and Empower®, Analytics in Action™ and Risk Pathways™.
We actively enforce our intellectual property rights to the fullest extent of the law and our intellectual property portfolio is constantly growing. The absence of an intellectual property right from this list pending update does not constitute a waiver of any of our intellectual property rights. Please contact our Intellectual Property Manager for further information.